ロード中...
Optimizing the treatment of BRAF mutant melanoma
Selective inhibitors of the kinases BRAF and MEK for the treatment of patients with otherwise refractory BRAF mutant melanoma have demonstrated impressive efficacy, and combination treatment with these agents may prove to be even more effective. However, these drugs are not curative, mainly because...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4062054/ https://ncbi.nlm.nih.gov/pubmed/25031620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/gm547 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|